Rapid Micro BiosystemsRPID
RPID
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0% more funds holding
Funds holding: 19 [Q3] → 19 (+0) [Q4]
15.87% less ownership
Funds ownership: 47.54% [Q3] → 31.67% (-15.87%) [Q4]
32% less capital invested
Capital invested by funds: $15.9M [Q3] → $10.8M (-$5.16M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$8
214%
upside
Avg. target
$8
214%
upside
High target
$8
214%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Keybanc Paul Knight 22% 1-year accuracy 2 / 9 met price target | 214%upside $8 | Overweight Initiated | 12 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced the grants (i) on March 3, 2025, of 50,000 restricted stock units (“RSUs”) of the Company's Class A common stock (“Common Stock”) as a material inducement to employment of one new employee and (ii) on March 10, 2025, of non-qualified stock options to purchase an aggregate of 250,000 shares of Common Stock (the “Options”) and 174,000 RSUs as a material inducement to employment to two new employees. All such equity awards were made under the Company's Inducement Plan, as amended (the “Inducement Plan”) and were approved by a majority of the independent directors of the Board of Directors or a duly authorized committee thereof in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards are subject to the terms and conditions of the Inducement Plan, and the terms and conditions of the applicable stock option and RSU award agreements covering the grants.
Neutral
Seeking Alpha
1 month ago
Rapid Micro Biosystems, Inc. (RPID) Q4 2024 Earnings Call Transcript
Rapid Micro Biosystems, Inc. (NASDAQ:RPID ) Q4 2024 Earnings Conference Call February 28, 2025 8:00 AM ET Company Participants Mike Beaulieu – Vice President, Investor Relations and Corporate Communications Rob Spignesi – President and Chief Executive Officer Sean Wirtjes – Chief Financial Officer Conference Call Participants Dan Arias – Stifel Paul Knight – KeyBanc Brendan Smith – TD Cowen Operator Thank you for standing by. My name is Eloisa, and I will be your conference operator today.
Negative
Zacks Investment Research
1 month ago
Rapid Micro Biosystems, Inc. (RPID) Reports Q4 Loss, Tops Revenue Estimates
Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.26 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the fourth quarter and full year ended December 31, 2024.
Neutral
GlobeNewsWire
1 month ago
Rapid Micro Biosystems Announces Global Distribution and Collaboration Agreement with the Life Science business of Merck KGaA, Darmstadt, Germany
Significantly extends commercial reach of Growth Direct through expanded global sales channels; enables opportunities for collaboration on supply chain efficiencies, services, and joint product development. Significantly extends commercial reach of Growth Direct through expanded global sales channels; enables opportunities for collaboration on supply chain efficiencies, services, and joint product development.
Neutral
GlobeNewsWire
1 month ago
Rapid Micro Biosystems to Participate in Upcoming Investor Conferences
LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the following investor conferences.
Neutral
GlobeNewsWire
1 month ago
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025
LEXINGTON, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release fourth quarter and full year 2024 financial results prior to the market open on Friday, February 28, 2025.
Neutral
GlobeNewsWire
2 months ago
Rapid Micro Biosystems Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenue
LEXINGTON, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced preliminary unaudited fourth quarter and full year 2024 revenue.
Neutral
GlobeNewsWire
2 months ago
Rapid Micro Biosystems to Present at 43ʳᵈ Annual J.P. Morgan Healthcare Conference
LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference.
Neutral
GlobeNewsWire
4 months ago
Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference
LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference.
Charts implemented using Lightweight Charts™